Cargando…
Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH–DR5-B with Dual VEGFR2 and DR5 Receptor Specificity
In the last two decades, bifunctional proteins have been created by genetic and protein engineering methods to increase therapeutic effects in various diseases, including cancer. Unlike conventional small molecule or monotargeted drugs, bifunctional proteins have increased biological activity while...
Autores principales: | Yagolovich, Anne V., Artykov, Artem A., Isakova, Alina A., Vorontsova, Yekaterina V., Dolgikh, Dmitry A., Kirpichnikov, Mikhail P., Gasparian, Marine E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9180153/ https://www.ncbi.nlm.nih.gov/pubmed/35682540 http://dx.doi.org/10.3390/ijms23115860 |
Ejemplares similares
-
Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL
por: Artykov, Artem A., et al.
Publicado: (2021) -
Corrigendum: Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL
por: Artykov, Artem A., et al.
Publicado: (2022) -
Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile
por: Yagolovich, Anne V., et al.
Publicado: (2020) -
DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma
por: Yagolovich, Anne V., et al.
Publicado: (2022) -
Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells
por: Yagolovich, Anne, et al.
Publicado: (2021)